Shuhendler AJ - Search Results

1

Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.

Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Li Y, et al. Among authors: shuhendler aj. J Control Release. 2008 May 22;128(1):60-70. doi: 10.1016/j.jconrel.2008.02.014. Epub 2008 Mar 5. J Control Release. 2008. PMID: 18406489

2

Thermally-triggered 'off-on-off' response of gadolinium-hydrogel-lipid hybrid nanoparticles defines a customizable temperature window for non-invasive magnetic resonance imaging thermometry.

Shuhendler AJ, Staruch R, Oakden W, Gordijo CR, Rauth AM, Stanisz GJ, Chopra R, Wu XY. Shuhendler AJ, et al. J Control Release. 2012 Feb 10;157(3):478-84. doi: 10.1016/j.jconrel.2011.09.061. Epub 2011 Sep 10. J Control Release. 2012. PMID: 21939700

3

On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Shuhendler AJ, O'Brien PJ, Rauth AM, Wu XY. Shuhendler AJ, et al. Drug Metabol Drug Interact. 2007;22(4):201-33. doi: 10.1515/dmdi.2007.22.4.201. Drug Metabol Drug Interact. 2007. PMID: 18447000

4

A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.

Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. Shuhendler AJ, et al. Breast Cancer Res Treat. 2010 Jan;119(2):255-69. doi: 10.1007/s10549-008-0271-3. Epub 2009 Feb 17. Breast Cancer Res Treat. 2010. PMID: 19221875

5

Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue.

Shuhendler AJ, Prasad P, Chan HK, Gordijo CR, Soroushian B, Kolios M, Yu K, O'Brien PJ, Rauth AM, Wu XY. Shuhendler AJ, et al. ACS Nano. 2011 Mar 22;5(3):1958-66. doi: 10.1021/nn103024b. Epub 2011 Feb 21. ACS Nano. 2011. PMID: 21338075

6

A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.

Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. Shuhendler AJ, et al. Adv Healthc Mater. 2012 Sep;1(5):600-8. doi: 10.1002/adhm.201200006. Epub 2012 Jul 25. Adv Healthc Mater. 2012. PMID: 23184795

7

Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.

Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM, Wu XY. Shuhendler AJ, et al. Mol Pharm. 2014 Aug 4;11(8):2659-74. doi: 10.1021/mp500093c. Epub 2014 Jun 3. Mol Pharm. 2014. PMID: 24830351

8

Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells.

Cheng J, Liu Q, Shuhendler AJ, Rauth AM, Wu XY. Cheng J, et al. Among authors: shuhendler aj. Colloids Surf B Biointerfaces. 2015 Jun 1;130:164-72. doi: 10.1016/j.colsurfb.2015.04.002. Epub 2015 Apr 8. Colloids Surf B Biointerfaces. 2015. PMID: 25896537

9

Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.

Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY. Prasad P, et al. Cancer Lett. 2013 Jul 1;334(2):263-73. doi: 10.1016/j.canlet.2012.08.008. Epub 2012 Aug 15. Cancer Lett. 2013. PMID: 22902994

10

A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.

Prasad P, Cheng J, Shuhendler A, Rauth AM, Wu XY. Prasad P, et al. Drug Deliv Transl Res. 2012 Apr;2(2):95-105. doi: 10.1007/s13346-011-0051-1. Drug Deliv Transl Res. 2012. PMID: 25786718

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters